MedDeviceGuideMedDeviceGuide
Topic

Commercialization

203 articles

Regulatory

Australia ARTG Sponsor Map: Who Controls Market Access for 63,000 Devices?

Analysis of Australia's ARTG reveals 3,377 sponsors managing 63,131 device listings — top 10 sponsors control 22%, and Emergo Australia represents 375 overseas manufacturers.

›
Regulatory

Bahrain NHRA: 3 ARs Hold 55% of Devices — Small GCC Market Channel Lock-In

Bahrain NHRA device database analysis: 62 ARs manage 1,491 devices, top 3 hold 55%, all tracked licenses expired, and manufacturer-AR lock-in is high. GCC channel strategy implications.

›
Regulatory

Canada MDALL Class III/IV Analysis: US Companies Hold 48% of High-Risk Listings

US companies hold 48% of Canada's 57,000 Class III/IV MDALL listings. Median device age is 9.7 years and 49% of devices are over a decade old. Full data analysis.

›
Regulatory

KIMES 2026: 977 Exhibitors, 78% Korean, Surgical Leads — Korea Export Push

KIMES 2026 exhibitor analysis: 977 companies, 78% Korean, surgical devices lead at 259 exhibitors, 94% export-ready. China tops international pavilion with 81 companies.

›
Regulatory

Korea MFDS: J&J, Medtronic, Stryker Dominate High-Risk Device Imports

Korea MFDS data shows 13,117 licence holders manage 273,672 registrations. Top 20 holders control 14.4%. US firms dominate Class III/IV imports at 30.4%.

›
Regulatory

Malaysia MDA: 2,462 Establishments, 23% Expiry Cliff, J&J at 58% Renewal

Malaysia MDA 49,198-row device dataset reveals 2,462 establishments with top-20 concentration at 18.7% and 11,438 devices expiring by end 2027. Data-driven establishment selection insights.

›
Regulatory

Mexico COFEPRIS Registration Holders: 5,286 Holders and the 2024 Volume Surge

Analysis of Mexico's 16,473 COFEPRIS registrations reveals 5,286 holders, 60% single-registration, diagnostics dominance at 37%, and a 2024 record peak.

›
Regulatory

Qatar's 2,623 Implantable Devices: 62% in 20 Suppliers, Lebanese Lock-In

Qatar MoPH implantable device register: 2,623 devices, 171 suppliers, top 20 control 62%. Lebanese distributor dominance and single-supplier manufacturer lock-in analyzed.

›
Regulatory

Saudi SFDA AR Concentration: 1,608 ARs, 35% in 20 Hands, 13,700 Expiry Cliff

Saudi SFDA 56,737-row device database: 1,608 ARs, top-20 concentration at 35.4%, and 13,717 devices expiring 2026-2027. Data-driven AR selection insights.

›
Regulatory

UAE EDE: 10 Suppliers Control a Third of All Medical Device Registrations

UAE EDE data shows 10 suppliers control 33.7% of 4,793 medical device registrations. Cigalah, Pharmatrade lead. US tops country of origin at 16%. Dubai holds 63.5% of registrations.

›
Regulatory

FDA Medical Device Registration: Step-by-Step Process from Classification to Market

Step-by-step FDA medical device registration — classification, 510(k)/De Novo/PMA pathways, establishment registration, device listing, FY 2026 fees, and post-market obligations.

›
Regulatory

Dermal Fillers vs Cosmetics vs Medicines: Hong Kong Borderline Classification After GN-00

How Hong Kong classifies injectable dermal fillers at the borderline between medical devices, cosmetics, and medicines — and why the May 2026 GN-00 update matters for your product.

›
Regulatory

Hong Kong Dermal Filler MDACS Listing Strategy: LRP, Docs, Importers, Procurement

Guide to listing injectable dermal fillers under Hong Kong MDACS after the May 2026 GN-00 update: LRP, technical dossier, importer controls, adverse event reporting, and procurement.

›
Regulatory

Hong Kong MDACS GN-00 Update: Why Injectable Dermal Fillers Are Now Medical Devices

On 13 May 2026, Hong Kong MDD updated GN-00 to classify injectable dermal fillers as medical devices under MDACS. What changed, why it matters, and what manufacturers must do.

›
M&A & Funding

Embecta-Owen Mumford $201M Deal: Auto-Injectors and Drug Delivery

Analysis of Embecta's Owen Mumford acquisition, including deal terms, Aidaptus auto-injector technology, diabetes business diversification, and GLP-1 drug-device strategy.

›
Digital Health & AI

Connected Autoinjectors and Smart Pens: Drug Delivery Pathways in 2026

Regulatory guide to connected autoinjectors and smart pens, covering FDA 510(k), De Novo, EU MDR classification, SaMD accessory issues, cybersecurity, and human factors.

›
Regulatory

Ecuador ARCSA Medical Device Registration Guide: 2026 Requirements

Guide to Ecuador ARCSA registration for medical devices and IVDs under the April 2026 rules, covering classification, documentation, fees, timelines, and post-market obligations.

›
Regulatory

Jordan JFDA Medical Device Registration: Requirements, Process and Timeline

Guide to registering medical devices and IVDs with Jordan's JFDA, covering classification, documentation, process steps, fees, timelines, authorized representatives, and post-market obligations.

›
Regulatory

UK MHRA 2026 Overhaul: CE Mark Recognition, DORS Fees and Clinical Trials

Overview of MHRA's 2026 device reforms, including CE mark recognition, DORS fees, clinical trial changes and manufacturer compliance steps for Great Britain.

›
Reimbursement & Market Access

ASC Expansion 2026: CMS Final Rule and Medtech Commercial Strategy

How the CMS CY 2026 OPPS/ASC Final Rule adds 573 procedures, phases out inpatient-only limits, expands device payment opportunities, and reshapes medtech commercialization.

›